H.C. Wainwright Reiterates ‘Buy’ Rating on Day One Biopharmaceuticals, Inc. (DAWN)

With significant hedge fund interest and a share price under $10, Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) secures a spot on our list of the 11 Best Single Digit Stocks to Buy According to Hedge Funds.

H.C. Wainwright Reiterates ‘Buy’ Rating on Day One Biopharmaceuticals, Inc. (DAWN)

A dose bottle of the medication is in the medical tech’s hand

On August 6, 2025, H.C. Wainwright reiterated its ‘Buy’ rating on Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) with a $25 price target. Meanwhile, on the same day, JPMorgan also maintained its ‘Buy’ rating, citing the strong growth trajectory of Ojemda for recurrent or refractory pediatric low-grade glioma (r/r pLGG). The U.S. peak sales for the medicine are projected to surpass $500 million.

Furthermore, the investment firm highlighted the company’s guidance for 2025 of $140-150 million in sales, underpinned by robust patient starts, persistence rates, and stable gross-to-net (GTN) ratios, which are expected to remain steady despite the recent price increase. Meanwhile, Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)’s sequential quarterly growth in patient volume continues. Lastly, the analyst cited the awaited update from the FIREFLY-1 Cohort 1 study on Ojemda’s long-term safety and efficacy. Positive results from the study could further strengthen confidence in the drug’s market potential.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) develops targeted therapies for childhood and adult cancers. It is included in our list of the Best Single Digit Stocks.

While we acknowledge the potential of DAWN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DAWN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.